Fibromyalgia Drug Market Will Nearly Quadruple to $2 Billion By 2016
Posted on: Monday, 6 August 2007, 09:18 CDT
WALTHAM, Mass., Aug. 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the recent approval of Pfizer's Lyrica (pregabalin) to treat fibromyalgia and the entry of several new drugs over the next decade will drive the fibromyalgia drug market to nearly quadruple and reach $2 billion in 2016
The new Pharmacor report Fibromyalgia finds that the market to treat the disease, which drug companies have only recently begun to tap, mostly for secondary indications, will continue to be characterized by polytherapy; most patients will be prescribed combinations of antidepressants, analgesics, and/or sedative hypnotics. If approved for fibromyalgia, drugs that will be used in combination therapy to treat the disorder will include Eli Lilly's Cymbalta, Cypress/Forest's milnacipran, Wyeth's desvenlafaxine, Pfizer's Neurontin, Schwarz's lacosamide, and Sepracor's Lunesta.
The report finds that, although the market to treat fibromyalgia in the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan will flourish in the next decade, the limited efficacy and tolerability of treatments will constrain the overall sales of most drugs.
"Fibromyalgia is very difficult to treat, and its symptoms -- which can include musculoskeletal pain, depression, and sleep dysfunction -- vary widely from patient to patient," said Kate Hohenberg, director at Decision Resources. "Even the leading new drugs for fibromyalgia will have drawbacks in efficacy and tolerability, and, as a result, there is still a large opportunity for drug developers."
About Fibromyalgia
More than 14 million people in the world's major pharmaceutical markets suffer from fibromyalgia, a syndrome of chronic widespread musculoskeletal pain with accompanying functional and sleep disorders. The vast majority of current cases are not diagnosed or treated by a physician, and even those who do receive drug therapy experience only modest relief from available agents.
About Decision Resources
Decision Resources (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 emarshall@dresources.com
Decision Resources
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,+1-781-296-2563, emarshall@dresources.com
Web site: http://www.decisionresources.com/
Source: PRNewswire
Related Articles
- China's Breast Cancer Drug Market Will Grow From $165 Million in 2008 to $298 Million In 2013
- Driven by Launch of Emerging Therapies, Overall Prostate Cancer Drug Market Will Increase by $2 Billion Through 2018
- China's Rheumatoid Arthritis Drug Market Will More than Double by 2013
- Growth in the Parkinson's Disease Drug Market, Fueled by the Launch of Several New Therapies, Will be Offset by Generic Erosion of Key Agents
- Celgene's Vidaza and Revlimid Will Capture 70 Percent of the Myelodysplastic Syndromes Drug Market
- Small-Cell Lung Cancer Drug Market Will More Than Double to Over $684 Million in 2017
- Generic Erosion Will Constrain Prostate Cancer Drug Market, Resulting in Annual Growth of Less Than 2 Percent Through 2012
- Novel Glycopeptides and Cephalosporins Will Drive the Hospital-Acquired Infections Drug Market Through 2017
- Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
- New Drugs From Novartis and Daiichi Sankyo Will Achieve Blockbuster Status in the Hypertension Drug Market
 |
 |
User Comments (0)
RSS Feeds